Cit­ing tox­i­c­i­ty con­cerns, Boehringer In­gel­heim drops short-lived IPF pact — keep­ing $1B+ in its pock­et

Boehringer In­gel­heim has qui­et­ly killed a short-lived deal that it was pre­pared to spend $1.25 bil­lion on, re­turn­ing an ear­ly-stage drug to its Ko­re­an biotech part­ner.

When the Ger­man phar­ma paid Bridge Bio­ther­a­peu­tics $50 mil­lion last Ju­ly, it hailed BBT-877 — an au­to­tax­in in­hibitor — as a po­ten­tial next-gen­er­a­tion treat­ment op­tion for fi­bros­ing in­ter­sti­tial lung dis­eases. But tox­i­c­i­ty con­cerns have cropped up, trig­ger­ing the de­ci­sion to drop the pro­gram, ac­cord­ing to Ko­rea Bio­med­ical Re­view.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER